［1］CHAN JK，TEOH D，HU JM，et al.Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types?A study of 1411 clear cell ovarian cancers［J］.Gynecol Oncol，2008,109(3)：370-376.
［2］TAKANO M，TSUDA H，SUGIYAMA T.Clear cell carcinoma of the ovary：is there a role of histology-specific treatment［J］.J Exp Clin Cancer Res，2012,31(1)：53.
［3］TORRE LA，TRABERT B，DESANTIS CE，et al.Ovarian cancer statistics，2018［J］.CA Cancer J Clin，2018,68(4)：284-296.
［4］ITAMOCHI H，OISHI T，OUMI N，et al.Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma［J］.Br J Cancer，2017,117(5)：717-724.
［5］JONES S，WANG TL，SHIH IEM，et al.Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma［J］.Science，2010,330(6001)：228-231.
［6］MITTAL P,ROBERTS CWM.The SWI/SNF complex in cancer-biology，biomarkers and therapy［J］.Nat Rev Clin Oncol，2020,17(7)：435-448.
［7］SATO E，NAKAYAMA K，RAZIA S，et al.ARID1B as a potential therapeutic target for ARID1A-mutant ovarian clear cell carcinoma［J］.Int J Mol Sci，2018,19(6)：1710.
［8］BOLTON KL，CHEN D，RI CORONA DE LA FUENTE，et al.Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes［J］.Clin Cancer Res，2022,28(22):4947-4956
［9］SAMANTA S，TAMURA S，DUBEAU L，et al.Clinicopathological significance of endoplasmic reticulum stress proteins in ovarian carcinoma［J］.Sci Rep，2020,10(1)：2160.
［10］ZUNDELL JA，FUKUMOTO T，LIN J，et al.Targeting the IRE1α/XBP1 endoplasmic reticulum stress response pathway in ARID1A-mutant ovarian cancers［J］.Cancer Res，2021,81(20)：5325-5335.
［11］CHEN Y，TSAI YH，TSENG SH.HDAC inhibitors and RECK modulate endoplasmic reticulum stress in tumor cells［J］.Int J Mol Sci，2017,18(2)：258.
［12］YANO M，YASUDA M，SAKAKI M，et al.Association of histone deacetylase expression with histology and prognosis of ovarian cancer［J］.Oncol Lett，2018,15(3)：3524-3531.
［13］BITLER BG，WU S，PARK PH，et al.ARID1A-mutated ovarian cancers depend on HDAC6 activity［J］.Nat Cell Biol，2017,19(8)：962-973.
［14］KWAN SY，CHENG X，TSANG YT，et al.Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells［J］.Oncotarget，2016,7(35)：56933-56943.
［15］MONK BJ，KAUDERER JT，MOXLEY KM，et al.A phase Ⅱ evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian，fallopian tube or primary peritoneal cancer：An NRG oncology/gynecologic oncology group study［J］.Gynecol Oncol，2018,151(3)：422-427.
［16］OGIWARA H，TAKAHASHI K，SASAKI M，et al.Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers［J］.Cancer Cell，2019,35(2)：177-190.e8.
［17］ZHANG J，PAVLOVA NN，THOMPSON CB.Cancer cell metabolism：the essential role of the nonessential amino acid，glutamine［J］.Embo J，2017,36(10)：1302-1315.
［18］WU S，FUKUMOTO T，LIN J，et al.Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma［J］.Nat Cancer，2021,2(2)：189-200.
［19］EDWARDS DN，NGWA VM，RAYBUCK AL，et al.Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer［J］.J Clin Invest，2021,131(4)：e140100.
［20］HU G，TU W，YANG L，et al.ARID1A deficiency and immune checkpoint blockade therapy：From mechanisms to clinical application［J］.Cancer Letters，2020,473：148-155.
［21］KURODA Y，CHIYODA T，KAWAIDA M，et al.ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer［J］.Gynecol Oncol，2021,162(3)：679-685.
［22］KHALIQUE S，NASH S，MANSFIELD D，et al.Quantitative assessment and prognostic associations of the immune landscape in ovarian clear cell carcinoma［J］.Cancers(Basel)，2021,13(15)：3854.
［23］PERANZONI E，LEMOINE J，VIMEUX L，et al.Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment［J］.Proc Natl Acad Sci USA，2018,115(17)：E4041-E4050.
［24］KHALIQUE S，LORD CJ，BANERJEE S，et al.Translational genomics of ovarian clear cell carcinoma［J］.Semin Cancer Biol，2020,61：121-131.
［25］SASANO T，MABUCHI S，KURODA H，et al.Preclinical efficacy for AKT targeting in clear cell carcinoma of the ovary［J］.Mol Cancer Res，2015,13(4)：795-806.
［26］LIN YH，CHEN BY，LAI WT，et al.The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel(Taxol) and cisplatin in ovarian cancer cells［J］.Naunyn Schmiedebergs Arch Pharmacol，2015,388(1)：19-31.
［27］FARLEY JH，BRADY WE，FUJIWARA K，et al.A phase Ⅱ evaluation of temsirolimus in combination with carboplatin and paclitaxel followed by temsirolimus consolidation as first-line therapy in the treatment of stage Ⅲ-Ⅳ clear cell carcinoma of the ovary［J］.Journal of Clinical Oncology，2016,34(15_suppl)：5531.
［28］XIAO Y，YU Y，JIANG P，et al.The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis［J］.Cell Oncol(Dordr)，2020,43(4)：669-680.
［29］OISHI T，ITAMOCHI H，KUDOH A，et al.The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma［J］.Oncol Rep，2014,32(2)：553-558.
［30］KASHIYAMA T，ODA K，IKEDA Y，et al.Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423［J］.PLoS One，2014,9(2)：e87220.
［31］BAGRATUNI T，MAVRIANOU N，GAVALAS NG，et al.JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer［J］.European Journal of Cancer，2020,126：125-135.
［32］SHIGETA S，LUI GY，SHAW R，et al.Targeting BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition as a therapeutic strategy for ovarian clear cell carcinoma［J］.Mol Cancer Ther，2021,20(4)：691-703.
［33］MAKII C，IKEDA Y，ODA K，et al.Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma［J］.Gynecol Oncol，2019,155(2)：331-339.
［34］CAUMANNS JJ，VAN WIJNGAARDEN A，KOL A，et al.Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma［J］.Cancer Lett，2019,461：102-111.
［35］RAMESH A，NATARAJAN SK，NANDI D，et al.Dual inhibitors-loaded nanotherapeutics that target kinase signaling pathways synergize with immune checkpoint inhibitor［J］.Cell Mol Bioeng，2019,12(5)：357-373.
［36］BURNS MB，TEMIZ NA，HARRIS RS.Evidence for APOBEC3B mutagenesis in multiple human cancers［J］.Nat Genet，2013,45(9)：977-983.
［37］WANG YK，BASHASHATI A，ANGLESIO MS，et al.Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes［J］.Nat Genet，2017，49(6)：856-865.
［38］YIN X，BI R，MA P，et al.Multiregion whole-genome sequencing depicts intratumour heterogeneity and punctuated evolution in ovarian clear cell carcinoma［J］.Journal of Medical Genetics，2020，57(9)：605.
［39］KURODA Y，CHIYODA T，KAWAIDA M，et al.ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer［J］.Gynecol Oncol，2021，162(3):679-685.
［40］HAMANISHI J，MANDAI M，IKEDA T，et al.Safety and antitumor activity of anti-PD-1 antibody，nivolumab，in patients with platinum-resistant ovarian cancer［J］.J Clin Oncol，2015,33(34)：4015-4022.
［41］MATULONIS UA，SHAPIRA-FROMMER R，SANTIN AD，et al.Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer：results from the phase Ⅱ KEYNOTE-100 study［J］.Ann Oncol，2019,30(7)：1080-1087.
［42］ZAMARIN D，BURGER RA，SILL MW，et al.Randomized phase Ⅱ trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer：An NRG oncology study［J］.Journal of Clinical Oncology，2020,38(16)：1814-1823.
［43］SIA TY，MANNING-GEIST B，GORDHANDAS S，et al.Treatment of ovarian clear cell carcinoma with immune checkpoint blockade：a case series［J］.Int J Gynecol Cancer，2022,32(8)：1017-1024.
［44］YANG J，YAN J，LIU B.Targeting VEGF/VEGFR to modulate antitumor immunity［J］.Front Immunol，2018,9：978.
［45］LIN YC，WEN KC，SUNG PL，et al.Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy：a case report［J］.J Ovarian Res，2020,13(1)：143.
［46］LI R，LIU X，SONG C，et al.Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma(INOVA)：an investigator-initiated，multicentre clinical trial-a study protocol of clinical trial［J］.BMJ Open，2022,12(5)：e058132.